Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 13/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24191167 | 0.90 | TSHR (0.47) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL11223507 | 0.83 | SMN1; SMN2 (0.49) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| Phthalic Acid SCHEMBL27722618 | 0.83 | THRB (0.40) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL8492483 | 0.82 | THRB (0.51) | ADRB2ADRB1ADRB3THRBSMN1; SMN2 | |
| SCHEMBL19316664 | 0.82 | ADRB2 (0.38) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL24571157 | 0.81 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL18392498 | 0.81 | TSHR (0.43) | ADRB2ADRB1ADRB3TSHRTHRB | |
| SCHEMBL2531577 | 0.81 | TSHR (0.56) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL36451 | 0.81 | TSHR (0.53) | TSHRALDH1A1THRBSMN1; SMN2CYP3A4 | |
| SCHEMBL23964584 | 0.81 | TSHR (0.53) | TSHRALDH1A1THRBSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | H1-0, VMP1, CHRM1 | ADRB2 735/4885ADRB1 850/4885ADRB3 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.